Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$1.36 - $2.94 $56,354 - $121,824
-41,437 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$2.97 - $4.84 $6,435 - $10,488
-2,167 Reduced 4.97%
41,437 $125,000
Q2 2021

Aug 10, 2021

BUY
$3.71 - $5.13 $71,105 - $98,321
19,166 Added 78.43%
43,604 $201,000
Q1 2021

May 17, 2021

BUY
$4.08 - $14.75 $1,770 - $6,401
434 Added 1.81%
24,438 $105,000
Q4 2020

Feb 12, 2021

SELL
$11.06 - $14.01 $12,221 - $15,481
-1,105 Reduced 4.4%
24,004 $265,000
Q3 2020

Nov 13, 2020

SELL
$10.26 - $14.55 $35,109 - $49,790
-3,422 Reduced 11.99%
25,109 $304,000
Q2 2020

Aug 05, 2020

BUY
$7.11 - $13.76 $27,195 - $52,632
3,825 Added 15.48%
28,531 $393,000
Q1 2020

May 14, 2020

SELL
$5.71 - $15.85 $20,578 - $57,123
-3,604 Reduced 12.73%
24,706 $191,000
Q4 2019

Feb 13, 2020

BUY
$9.6 - $17.75 $135,523 - $250,576
14,117 Added 99.46%
28,310 $432,000
Q3 2019

Nov 12, 2019

SELL
$12.16 - $21.0 $9,618 - $16,611
-791 Reduced 5.28%
14,193 $173,000
Q2 2019

Aug 13, 2019

SELL
$9.44 - $19.8 $61,161 - $128,284
-6,479 Reduced 30.19%
14,984 $297,000
Q1 2019

May 14, 2019

SELL
$11.11 - $13.49 $33,685 - $40,901
-3,032 Reduced 12.38%
21,463 $263,000
Q4 2018

Feb 05, 2019

SELL
$10.24 - $15.49 $19,671 - $29,756
-1,921 Reduced 7.27%
24,495 $311,000
Q3 2018

Nov 14, 2018

SELL
$15.53 - $19.97 $293,485 - $377,393
-18,898 Reduced 41.7%
26,416 $411,000
Q2 2018

Aug 10, 2018

BUY
$15.88 - $19.5 $11,211 - $13,767
706 Added 1.58%
45,314 $846,000
Q1 2018

May 14, 2018

BUY
$13.53 - $17.47 $320,309 - $413,584
23,674 Added 113.09%
44,608 $759,000
Q4 2017

Feb 14, 2018

BUY
$14.41 - $19.15 $301,658 - $400,886
20,934
20,934 $333,000

Others Institutions Holding ATNX

About Athenex, Inc.


  • Ticker ATNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 156,790,000
  • Market Cap $1.57M
  • Description
  • Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...
More about ATNX
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.